Medical therapy of gastroesophageal reflux disease in secondary and tertiary care settings

Yale Journal of Biology and Medicine

Volumn 72, Issue 2-3, 1999, Pages 219-226

  Tytgat, G N J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISAPRIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

DISEASE SEVERITY; ESOPHAGITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HUMAN; LOWER ESOPHAGUS SPHINCTER; REFLUX ESOPHAGITIS; REVIEW; SYMPTOMATOLOGY;

ANTACIDS; ESOPHAGITIS, PEPTIC; GASTRIC JUICE; GASTROESOPHAGEAL REFLUX; HISTAMINE H2 ANTAGONISTS; HUMANS; HYDROGEN-ION CONCENTRATION; PROTON PUMPS; PROTON-TRANSLOCATING ATPASES;

HELICOBACTER PYLORI;

EID: 0033490459     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Ellis, K.K., Oehike, M., Helfand, M., and Lieberman, D. Management of symptoms of gastroesophageal reflux disease: does endoscopy influence medical management? Am. J. Gastroenterol. 92:1472-1474, 1997.
2. Schoeman, M.N., De, M., Tippett, M., Akkermans, L.M.A., Dent, J., and Holloway, R.H. Mechanisms of gastroesophageal reflux in ambulant healthy human subjects. Gastroenterology 108:83-91, 1995.
3. Mittal, R.K., Holloway, R.H., Penagini, R., Blackshaw, L.A., and Dent, J. Transient lower esophageal sphincter relaxation, gastroenterology 109:601-610, 1995.
4. Mittal, R.K. and Balaban, D.H. The Esophagogastric Junction. New Engl. J. Med. 336:924-932, 1997.
5. Tytgat, G.N.J. Long term therapy for reflux esophagitis. New Engl. J. Med. 333:1148-1150, 1995.
6. Tytgat, G.N.J., Janssens, J., Reynolds. J.C., and Wienbeck, M. Update on the pathophysiology and management of gastrooesophageal reflux disease: the role of prokinetic therapy. Eur. J. Gastroenterol. Hepatol. 8:603-611, 1996.
7. Hatlebakk, J.G. and Berstad, A. Gastrooesophageal reflux during 3 months of therapy with ranitidine in reflux oesophagitis. Scand. J. Gastroenterol. 31:954-958, 1996.
8. Chiba, N., De Gara, C.J., Wilkinson, J.M. et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112:1798-1810, 1997.
9. Bell, N.J. and Hunt, R.H. Role of gastric-acid suppression in the treatment of gastrooesophageal reflux disease. Gut 33:118-124, 1992.
10. Hunt, R.H. The relationship between the control of pH and healing and symptom relief in gastro-esophageal reflux disease. Aliment. Pharmacol. Then 9(suppl 1):3-7, 1995.
11. Howden, C.W. and Freston, J.W. Setting the "gold standards" in the management of gastroesophageal reflux disease. In: Gastroenterology Today, Vol. 6, No. 2; 1996.
12. Hatiebakk, J.G. and Berstad, A. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease. Clin. Pharmacolkinet.31:386-406, 1996.
13. Klinkenberg-Knol, E.C., Festen, H.P., and Jansen, J.B. et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann. Intern. Med. 121:161-167, 1994.
14. Leite, L.P., Johnston, B.T., Just, R.J., and Castell, D.O. Persistent acid secretion during omeprazole therapy: a study of gastric acid profile acid profiles in patients demonstrating failure of omeprazole therapy. Am. J. Gastroenterol. 91:8:1527-1531, 1996.
15. Hendel, J., Hendel, L., Hage, E., Hendel, J., Aggestrup, S., and Nielsen, O.H. Monitoring of omeprazole treatment in gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 8:417-420, 1996.
16. Carlsson, R., Galmiche, L-P., Dent, J., Lundell, L., and Frison, L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drug: a meta-analysis of long-term omeprazole trials. Aliment. Pharmacol. Ther. 11:473-482, 1997.
17. McDougall, N.I., Watson, R.G.P., Collins, J.S.A., McFarland, R.J., and Love, A.H. Maintenance therapy with cisapride after healing of erosive oesophagitis: a double-blind placebo-controlled trial. Aliment. Pharmacol. Ther. 11:487-495, 1997.
18. Hatiebakk, J.G., Johnsson, F., and Vilien, M. The effect of cisapride in maintaining symptomatic remission in patients with gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 1997. (Submitted).
19. Tytgat, G.N.J., Blum, A.L., and Verlinden, M. Prognostic factors for relapse and maitenance treatment with cisapride in gastroesophageal reflux disease. Aliment. Pharmacol. Ther. 9:271-280, 1995.
20. Carlsson, R., Galmiche, J.-P., Dent, J., Lundell, L., and Frison, L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment. Pharmacol. Ther. 11:473-482, 1997.
21. De Vault, K.R. and Castell, D.O., for the Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Arch. Intern. Med. 155:2165-2173, 1995.
22. El-Omar, E., Benedee, S., and Wirz, A. Marked rebound acid hypersecretion after treatment with ranitidine. Am. J. Gastroenterol. 91:355-359, 1996.
23. Waldum, H.L., Amestad, J.S., Brenna, E., Eide, I., Syversen, U., and Sandvik, A.K. Marked increase in gastric acid secretary capacity after omeprazole treatment. Gut 39:649-653, 1996.
24. Driman, D.K., Wright, C. and Tougas, G. Omeprazole produces pariental cell hypertrophy and hyperplasia in humans. Dig. Dis. Sci. 41:2039-2047, 1996.
25. Boeckxstaens, G.E., Hirsch, D.P., Fakhry, N., Holloway, R.H., D'Amato, M., and Tytgat, G.N.J. Involvement of cholecystokinin-A receptors in transient lower oesophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 93:1823-1828, 1998.
26. Venables, T.L., Newland, R.D., Patel, A.C., Hole, J., Wilcock, C., and Turbitt, M.L. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand. J. Gastroenterol. 32:965-973, 1997.
27. Galmiche, J.-P., Barthelemy, P., and Hamelin, B. Treating the symptoms of gastrooesophageal reflux disease: a double-blind comparison of omeprazole and cisapride. Aliment. Pharmacol. Ther. 11:765-773, 1997.
28. Bardham, K.D. Symptomatic GORD. Intermitent treatment with omeprazole and ranitidine as a strategy for management. DDW 1997. (Abstract 428).
29. Jones, R.H. Low-dose lansoprazole provides greater relief and epigastric pain than low dose Omeprazole in patients with acid-related dyspepsia. DDW 1997. (Abstract 512).
30. Lind, T., Havelund, T., Carlsson, R., Anker-Hansen, O., Glise, H., Hemqvist, H., Junghard, O., Lauritsen, K., Lundell, L., Pedersen, S.-A., and Stubberöd, A. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand. J. Gastroenterol. 32:974-979, 1997.